News from advanced accelerator applications A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 29, 2014, 10:01 ET

Kapil Dhingra, Former Head of Roche Oncology, Joins Advanced Accelerator Applications Board of Directors

Advanced Accelerator Applications S.A. ("AAA" or "the Company"), an international specialist in Molecular Nuclear Medicine, today announced that...

Mar 04, 2014, 07:00 ET

AAA Receives Orphan Drug Designation from FDA and EMA for Gallium-68 DOTATATE for Use in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors

Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM), announced today that they have...

Mar 04, 2014, 07:00 ET

Advanced Accelerator Applications Enters UK and Irish Nuclear Medicine Markets with the Acquisition of Imaging Equipment Ltd

 - The acquisition gives AAA its first direct sales presence in the UK and Ireland, expands its specialist nuclear medicine...

Feb 17, 2014, 07:00 ET

Advanced Accelerator Applications Completes €41 Million Fundraising

Highlights - HBM Healthcare Investments Ltd invests €20 million - The funds will be used to: - Accelerate the Company's...

Oct 16, 2013, 07:00 ET

AAA Reaches Halfway Recruitment Milestone of Cancer Patients in Lutathera® Pivotal Phase III Trial

Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM), announced today that the...

Feb 01, 2013, 07:00 ET

AAA Strengthens European Radiopharmaceutical Manufacturing Network

Highlights - Acquisition of two well established radiopharmaceutical companies in Barcelona, Spain - Entry into Polish market...

Sep 19, 2012, 09:00 ET

Start of Pivotal Phase III Trial for Lutathera® in Cancer Patients With Progressive Midgut Carcinoid

Highlights - Lutathera® is the first theragnostic drug in Molecular Nuclear Medicine (MNM) to enter phase III clinical development...